Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug-resistant, and deadly

Dubil, Elizabeth

282 - Poster Session A
Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug-resistant, and deadly

Saturday, March 22, 2014: 9:25 AM

West Exhibit Hall (Tampa Convention Center)

E. A. Dubil¹, W. Bshara², K. O. Odunsi², C. Morrison², C. Tian^3,4, J. I. Risinger⁵, G. L. Maxwell⁶, C. A. Hamilton¹, K. M. Darcy⁷ and W. Consortium³
¹Walter Reed National Military Medical Center, Bethesda, MD, ²Roswell Park Cancer Institute, Buffalo, NY, ³Women's Health Integrated Research Center, Annandale, VA, ⁴Precision Therapeutics, Inc., Pittsburgh, PA, ⁵Michigan State University, Grand Rapids, MI, ⁶Inova Fairfax Hospital, Falls Church, VA, ⁷Gynecologic Cancer Center of Excellence, Annandale, VA

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

282 - Poster Session A
Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug-resistant, and deadly

282 - Poster Session A Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug-resistant, and deadly

282 - Poster Session A
Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug-resistant, and deadly